Clinical Trials Logo

Gastroesophageal Reflux clinical trials

View clinical trials related to Gastroesophageal Reflux.

Filter by:

NCT ID: NCT01710995 Completed - Acid Reflux Clinical Trials

A Three-Period Study to Investigate the Relative Bioavailability and Pharmacodynamic Profiles of a Zegerid 20mg Capsule, Zegerid 20mg Powder for Oral Suspension and Losec 20mg Capsule in Healthy Adult Volunteers Under Fasting Conditions

Start date: October 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the effectiveness of Zegerid 20mg capsules and powder and Losec 20mg capsules in healthy volunteers under fasting conditions.

NCT ID: NCT01710462 Withdrawn - Clinical trials for Gastroesophageal Reflux Disease

Clinical Study, Multicenter, Randomized With 2 Arms of Pantoprazole + Domperidone and Pantoprazole Isolated at the Gastroesophageal Reflux Disease

PANDA
Start date: August 2013
Phase: Phase 3
Study type: Interventional

This superiority phase III study to compare the combination of Pantoprazole and Domperidone with Pantoprazole isolated to the treatment of gastroesophageal reflux disease. The hypothesis is that combination of the two medication at the unique capsule is better to the patients because decrease the quantity of times the patients need to take medicines during the day.

NCT ID: NCT01707901 Completed - GERD Clinical Trials

A Study of the Effect of ONO-8539 on Oesophageal Pain Hypersensitivity in Patients With Non-erosive Reflux Disease

Start date: December 2012
Phase: Phase 1
Study type: Interventional

A random controlled study to investigate the effect of a new drug, ONO-8539, on oesophageal pain hypersensitivity in patients with gastric reflux disease

NCT ID: NCT01696734 Recruiting - Clinical trials for Gastroesophageal Reflux Disease

Domperidone in Treating Patients With Gastrointestinal Disorders

Start date: October 23, 2012
Phase: Phase 3
Study type: Interventional

This phase III trial studies how well domperidone works in treating patients with gastrointestinal disorders. Domperidone may help control chronic gastrointestinal disorders and their symptoms, such as pain, bloating, and nausea and vomiting, by stimulating contraction of the stomach to increase its ability to empty itself of food.

NCT ID: NCT01682265 Completed - Clinical trials for Gastroesophageal Reflux Disease

Stretta In Reflux Uncontrolled by IPP

SIRUP
Start date: March 26, 2012
Phase: N/A
Study type: Interventional

The aim of the study is to compare the Stretta procedure and the Sham procedure efficiency 6months post-procedure in reflux uncontrolled by intake of Inhibitors of Protons Pump (IPP) patients.

NCT ID: NCT01669811 Completed - Clinical trials for Refractory Reflux Esophagitis

Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)

Start date: August 2012
Phase: Phase 3
Study type: Interventional

This is a phase 3 multicentre, randomised, double-blind, parallel-group, comparative study to evaluate the efficacy of esomeprazole (D961H) 20 mg twice daily and esomeprazole (D961H) 20 mg once daily in patients (in the form of esomeprazole magnesium salt) with refractory reflux esophagitis after 8 weeks of standard Proton-pump inhibitor (PPI) therapy by assessment of presence/absence of inflammation (esophagitis) at Week 8 according to the Los Angeles (LA) classification

NCT ID: NCT01669330 Completed - Clinical trials for Gastroesophageal Reflux

Laparoscopic Nissen Versus Anterior Partial Fundoplication

Start date: January 2001
Phase: N/A
Study type: Interventional

The most widely used operative technique for gastroesophageal reflux is total fundoplication where the gastric fundus is sutured around the distal esophagus like a wrap. This operation effectively prevents gastroesophageal reflux but gives rise to postoperative symptoms related to over-competence of the gastroesophageal junction. 40% of the operated patients experience increased flatulence and 20% dysphagia. Anterior fundoplication is an alternative technique where the distal esophagus is anchored to the crura of the hiatus esophagi and only a part of the front wall of the esophagus is covered with fundus. An anterior fundoplication is un attempt to create a more physiologic reflux control and less functional problems postoperatively. The aim with this study is to compare the results postoperatively, both short time and long time results.

NCT ID: NCT01667042 Completed - Scleroderma Lung Clinical Trials

Scleroderma Lung: Role of Gastroesophageal Reflux, Microaspiration and Cough

Start date: August 2012
Phase: N/A
Study type: Observational

This is a mechanistic research study to evaluate the relationship between cough, reflux, and aspiration in patients with systemic sclerosis (scleroderma).

NCT ID: NCT01657578 Completed - Clinical trials for Gastroesophageal Reflux Disease (GERD)

Optimal Dosing of Omeprazole in Neonates

OMEPRAZOLE-1
Start date: June 2007
Phase: Phase 2
Study type: Interventional

"The principal aim of this trial is to determine the minimum effective dose of omeprazole in neonates with GERD objectively diagnosed by a 24-h intra-oesophageal pH monitoring (pHmetry), to obtain a short-term efficacy in the pHmetry of control performed 72 hrs ± 24 after initiation of omeprazole. The secondary objectives of the study were: (1) to assess the efficacy of omeprazole upon other pHmetry parameters, (2) to characterize the population pharmacokinetics and pharmacogenetics of omeprazole, (3) to evaluate the effect of omeprazole upon oro-pharyngeal pH monitoring and (4) to assess the short-term safety of use of omeprazole in neonates."

NCT ID: NCT01647958 Completed - Clinical trials for Gastroesophageal Reflux Disease (GERD)

The EndoGastric Solutions TEMPO Trial

TEMPO
Start date: June 1, 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of Transoral Incisionless Fundoplication (TIF) performed with EsophyX as compared to proton pump inhibitor (PPI) therapy for the treatment of chronic Gastroesophageal Reflux Disease (GERD) patients with refractory symptoms on Proton Pump Inhibitors (PPIs).